comprehensive -WSS

comprehensive

author：knowledge 2025-09-29 01:09:42 - browse：3314

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Fentanyl is making it harder to start addiction treatment

WSS

Bird flu surveillance in wastewater gets boost from consortium

Study finds gene variants tied to breast cancer risk in Black women

Scrutiny of post

ASCO: AstraZeneca says CAR

FDA's Pazdur wants cancer trials to range beyond China alone

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

leisure time

comprehensive

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Investigation reveals sickle cell patients pressured into sterilizations

The cancer drug shortage isn’t new — and neither are the solutions

Eyeing GLP

Walensky prepares to leave CDC — and Congress — behind

Intellia reports positive results for its CRISPR

New air purifier tech could be key to improving indoor air quality

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Investigation reveals sickle cell patients pressured into sterilizations

hotspot

Letters to First Opinion on caregivers, digital health, and more

Investigation reveals sickle cell patients pressured into sterilizations

Investigation reveals sickle cell patients pressured into sterilizations

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Fentanyl is making it harder to start addiction treatment

Let's speed up science by embracing open access publishing

focus

hotspot

hotspot

hotspot